Business Paid
Urteste Nears FDA Decision on Panuri Pancreatic Cancer Test
19:11
Polish biotech company Urteste expects the FDA’s feedback on its Panuri diagnostic test assumptions by the end of March. Panuri aims to detect pancreatic cancer early through urine samples.
CEO Grzegorz Stefański noted that while key aspects of the study were agreed upon in a January FDA meeting, the agency requested…
This article is for subscribers
Warsaw Business Journal subscribers get the full archive (12,248 articles going back to 1995) and the print edition.
SubscribeOr try Poland A.M. free for 7 days, the daily briefing, or see all plans and prices.
